Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02232737
Other study ID # P50DA036114:P3S2
Secondary ID P50DA036114
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date October 7, 2016
Est. completion date January 14, 2019

Study information

Verified date October 2022
Source Brown University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will examine extended exposure to cigarettes varying in nicotine content among disadvantaged women. Adults with affective disorders are at increased risk for smoking, nicotine dependence, and using high nicotine yield cigarettes and are also at significantly increased risk for smoking-related adverse health consequences, including site-specific cancers, heart disease, and premature death. Studies testing an innovative regulatory strategy of reducing the nicotine content of cigarettes to a non-addictive level have shown promising beneficial effects (decreased smoking rate, reduced toxicant exposure, and increased cessation) in the general population of smokers. However, these studies have uniformly excluded vulnerable populations like those with affective disorders who may respond differently considering their greater vulnerability to smoking and nicotine dependence. Thus, little is known scientifically about how this highly vulnerable subgroup of smokers might respond to a nicotine reduction policy. This project is designed to address that substantial knowledge gap. This same study was also conducted in two additional vulnerable populations under a similar protocol.


Description:

The primary overall objective of these studies is to evaluate the effects of extended exposure to cigarettes differing in nicotine content in adult men and women with affective disorders using a 3-condition, parallel groups design. After a baseline period in which daily smoking rate and other baseline assessments are completed, participants will be randomly assigned to one of three cigarette conditions (nicotine content: 0.03, 0.12, and 0.8 mg nicotine of tobacco) for the 12-week experimental period. The cigarettes to be used in this study were made under an NIH contract with production being overseen by the Research Triangle Institute (referred to as "Spectrum cigarettes"). NIH currently has approximately 10 million of these cigarettes (of varying types) for research purposes. The cigarettes selected for the study span the range of yields likely to produce the hypothesized effects, as described above. The Spectrum cigarettes are not currently commercially available, although they are similar in many ways to marketed cigarettes (e.g., similar manufacturing, filter, paper, etc.). The primary overall objective of this study is to evaluate the effects of extended exposure to cigarettes differing in nicotine content in adult men and women with affective disorders using a 3-condition, parallel groups design. After a baseline period in which daily smoking rate and other baseline assessments are completed, participants will be randomly assigned to one of three cigarette conditions (nicotine content: 0.03 mg, 0.12 mg, and 0.8 mg nicotine of tobacco) for the 12-week experimental period. Participants will be seen weekly throughout the 12-week experimental period to obtain research cigarettes. Cigarettes smoked per day will be obtained by participants completing daily Interactive Voice Response (IVR) reports of cigarettes in past 24 hours. This daily data will be used to calculate weekly means, with week-12 means serving as the primary outcome. This same study was conducted in two additional vulnerable populations under a similar protocol, with differences between protocols consisting of data collection specific to that vulnerable population. This included information such as use and timing of opioid maintenance therapy for individuals with opioid-use disorder and other measures relevant to disadvantaged women of reproductive age. In order to explore potential differences across individuals with different vulnerabilities, data from all three studies were combined for analysis. A vulnerable population-by-condition or population-by-condition-by-time interaction term was included in all analyses. In the event that these interaction terms were statistically significant, all pairwise comparisons were conducted using a Bonferroni multiple comparison adjustment.


Recruitment information / eligibility

Status Completed
Enrollment 775
Est. completion date January 14, 2019
Est. primary completion date January 14, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Male or Female - Ages 18-70 - Past-year major depressive disorder, dysthymic disorder, generalized anxiety disorder, post-traumatic stress disorder, obsessive-compulsive disorder, phobia, or panic disorder with or without agoraphobia, based on Mini-Neuropsychiatric Interview (MINI) structured interview, OR lifetime diagnosis of one of the above based on MINI with a self-report of currently receiving treatment (prescribed psychoactive medication, behavioral therapy, etc.) - Report smoking 5 or more cigarettes per day for the past year - Provide an intake breath Carbon Monoxide (CO) sample > 8 ppm - Be without current substance abuse/dependence other than nicotine - Be sufficiently literate to complete the research-related tasks - Be in good physical health without serious illness or change in health in the past 3 months as determined by the licensed medical professional at each site - Not pregnant or nursing and report using oral, implant, patch, ring, intrauterine device (IUD), injection or barrier contraceptives or report being surgically sterile or post-menopausal - Report no significant use of other tobacco or nicotine products within the past month (> 9 days in the past 30) Exclusion Criteria: - Any prior regular use (used as primary cigarette outside of the laboratory) of Spectrum cigarettes (i.e., research cigarettes with reduced nicotine content) - Exclusive use of roll-your-own cigarettes - Planning to quit smoking in the next 30 days - A quit attempt in the past 30 days resulting in > 3 days of abstinence - Positive toxicology screen for illicit drugs not including marijuana (participants with valid prescriptions will not be excluded and participants with a positive toxicology screen will be allowed to re-screen once) - Breath alcohol level > 0.01 (participants with a positive screen will be allowed to re-screen once) - Self-report of binge drinking alcohol (> 9 days in the past 30, 4/5 drinks in 2 hours for women/men - Systolic blood pressure below 90 mmHg or greater than or equal to 160 mmHg (participants outside the range will be allowed to re-screen once) - Diastolic blood pressure below 50 mmHg or greater than or equal to 100 mmHg (participants outside the range will be allowed to re-screen once) - Breath CO > 80 ppm - Heart rate below 45 or greater than or equal to 115 bpm (participants outside the range will be allowed to re-screen once) - Currently seeking treatment for smoking cessation - Have used nicotine replacement, bupropion or other pharmacotherapies as cessation aids in the past month (bupropion for treatment of depression will be allowed) - Unstable psychiatric conditions (psychiatric medication changes in the past 4 weeks) - Current symptoms of psychosis, dementia or mania - Suicidal ideation in past month - Suicide attempt in past 6 months - Participation in another research study in the past 30 days

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Very low nicotine content cigarettes


Locations

Country Name City State
United States University of Vermont Burlington Vermont
United States Brown University Providence Rhode Island

Sponsors (3)

Lead Sponsor Collaborator
Brown University National Institute on Drug Abuse (NIDA), University of Vermont

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cigarettes Per Day (CPD) Participant reported number of cigarettes smoked per day at Week 12 12 weeks
See also
  Status Clinical Trial Phase
Withdrawn NCT02432066 - Effects of GTS-21 on Smoking Behavior and Neurocognitive Functions Phase 2
Completed NCT03960138 - Examining the Effects of Neural Stimulation on Inhibitory Control and Cigarette Smoking N/A
Recruiting NCT05030272 - Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings N/A
Completed NCT04646668 - Comparative Abuse Liability Among African American and White Smokers N/A
Completed NCT02560324 - Effect of Ramelteon on Smoking Abstinence Phase 2
Completed NCT02347605 - Medicinal Nicotine for Preventing Cue Induced Craving N/A
Completed NCT01570595 - Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV Phase 1/Phase 2
Completed NCT01428310 - Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke Phase 1
Completed NCT01625767 - Tobacco Approach Avoidance Training for Adolescent Smokers-1 Phase 2
Completed NCT01442753 - Family-Skills Training to Prevent Tobacco and Other Substance Use in Latino Youth N/A
Terminated NCT01800500 - Interest in Smokeless Tobacco Product as a Substitution for Cigarettes in Current Smokers N/A
Active, not recruiting NCT01539525 - Screening to Augment Referral to Treatment- Project START Phase 2
Completed NCT01337817 - A Pilot Study to Evaluate the Efficacy and Safety of Ariva® Silver Wintergreen in Healthy Smokers Phase 1
Completed NCT00967005 - N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers Phase 2
Active, not recruiting NCT00751660 - Screening Methods in Finding Lung Cancer Early in Current or Former Smokers N/A
Completed NCT00790569 - Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking N/A
Completed NCT00664261 - Clinical Effort Against Secondhand Smoke (CEASE) Program or Standard Care in Helping Parents Stop Smoking N/A
Completed NCT00158145 - Assessing the Variability Over Time of Tobacco Carcinogen Biomarkers in Smokers - 2 Phase 2
Completed NCT01213524 - Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia Phase 2
Completed NCT00218179 - Assessing the Link Between Smoke Carcinogen Biomarkers and Lung Cancer Risk - 1 N/A